CD4 and cancer: This observation suggested that cDC2s, despite being less potent APCs than cDC1s, still associate with favorable features of ECs such as a lower cancer stage, which arguably is due to migratory cDC2s’ capacity to drive effective CD4+ T-cell responses by priming naive cells in tumor-draining LNs [28].